Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 13/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2477102 | 1.00 | S1PR3 (0.45) | S1PR3TBXAS1NR4A1NR4A2NR4A3 | |
| SCHEMBL13326256 | 0.80 | S1PR3 (0.40) | S1PR3MRGPRX4ARS1PR1S1PR2 | |
| SCHEMBL26666684 | 0.80 | NR4A1 (0.46) | S1PR3TBXAS1NR4A1NR4A2NR4A3 | |
| SCHEMBL30737737 | 0.80 | S1PR3 (0.51) | S1PR3MRGPRX4ARS1PR1S1PR2 | |
| SCHEMBL2369495 | 0.80 | S1PR3 (0.51) | S1PR3MRGPRX4ARS1PR1S1PR2 | |
| SCHEMBL996704 | 0.80 | MRGPRX4 (0.56) | S1PR3MRGPRX4 | |
| SCHEMBL111301 | 0.80 | CES2 (0.52) | TBXAS1NR4A1NR4A2NR4A3F2 | |
| Hydrochloric Acid SCHEMBL6786928 | 0.78 | TBXAS1 (0.52) | TBXAS1NR4A1NR4A2NR4A3F2 | |
| SCHEMBL16961084 | 0.76 | S1PR3 (0.47) | S1PR3MRGPRX4ARS1PR1S1PR2 | |
| SCHEMBL6933705 | 0.76 | NR4A1 (0.47) | S1PR3TBXAS1NR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | S1PR3 3/4885TBXAS1 141/4885NR4A1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.